A double blind, double dummy, randomised, multicentre study to compare the efficacy and safety of fulvestrant [Faslodex] 250mg with Arimidex [anastrozole] 1mg as a secondary-line therapy in postmenopausal women with oestrogen receptor positive advanced breast cancer
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Fulvestrant (Primary) ; Anastrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 18 Dec 2007 Status changed from recruiting to completed.
- 23 Oct 2006 New trial record.